Advanced search
Publication Cover
Cancer Investigation Volume 28, 2010 - Issue 7
Submit an article Journal homepage
452
Views
35
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEImaging, Diagnosis, Prognosis

Immune Signatures Predict Prognosis in Localized Cancer

David S HsuDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Mickey K KimDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Bala S. BalakumaranDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Chaitanya R AcharyaDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Carey K AndersDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Tim ClayDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
H. Kim LyerlyDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Charles G. DrakeDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Michael A. MorseDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
&
Phillip G. FebboDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
 show all
Pages 765-773 | Published online: 22 Jun 2010
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the expression of genes recently associated with host immune responses (TH1-mediated adaptive immunity, inflammation, and immune suppression) to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors. Microarray data from prostate cancer (n = 79), breast cancer (n = 132), lung cancer (n = 84), glioblastoma multiforme (n = 120), and lymphoma (n = 127) were analyzed. Among adenocarcinomas, the TH1-mediated adaptive immunity genes were consistently associated with better prognosis, while genes associated with inflammation and immune suppression were variably associated with outcome. Specifically, increased expression of the TH1-mediated adaptive immunity genes was associated with good prognosis in breast cancer patients under 45 years of age (p = .04, hazard ratio [HR] = 0.42) and in prostate cancer patients (p = .03, HR = 0.36) but not in lung cancer patients (p = 0.45, HR = 1.37). In lymphoma, patients with increased expression of inflammation and immune suppression genes had better prognosis than those expressing the TH1-mediated adaptive immunity genes (p = .01, HR = 0.43) and in glioblastoma multiforme, the expression of inflammation genes conferred improved prognosis than those expressing immune suppression genes (p = 0.05, HR = 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.